Amgen’s Neulasta is set to face its first competition in the US after the FDA approved Mylan’s biosimilar version of the blockbuster cancer infection biologic. Neulasta brought in $4.5 billion ...

Intech Investment Management LLC bought a new stake in Coherus BioSciences, Inc. (NASDAQ:CHRS – Free Report) during the fourth quarter, according to the company in its most recent Form 13F filing with ...

Coherus BioSciences will see its workforce shrink once again as the result of the recently agreed sale of its Neulasta biosimilar to Accord BioPharma. About 50 employees who are associated with ...

Last week, Fresenius Kabi announced the launch of STIMUFEND (pegfilgrastim-fpgk), a biosimilar to Amgen’s NEULASTA, in the United States. As we previously reported, STIMUFEND was Fresenius Kabi ...

Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options ...

Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating ...

Pegfilgrastim biosimilars, including Neulasta, are instrumental in preventing chemotherapy-induced neutropenia by stimulating white blood cell production and reducing infection risks. The Neulasta ...

Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta ... Amgen also has a growing biosimilar portfolio. Following our analysis of ...